Can we use an ex vivo continuous hemofiltration model to describe the adsorption and elimination of meropenem and piperacillin?

International Journal of Artificial Organs

Volumn 38, Issue 8, 2015, Pages 419-424

  Jamal, Janattul Ain ^a   Udy, Andrew A ^b   Wallis, Steven C ^a   Ranganathan, Dwarakanathan ^c   McWhinney, Brett C ^d   Ungerer, Jacobus P J ^d   Lipman, Jeffrey ^a,c   Roberts, Jason A ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d Pathology Queensland   (Australia)

Author keywords

Ex vivo; Hemofiltration; Meropenem; Pharmacokinetic; Piperacillin; Renal replacement therapy

Indexed keywords

ADSORPTION; PHARMACOKINETICS;

CLINICAL STUDY; EX-VIVO; HEMOFILTRATION; MEROPENEM; OBSERVED DATA; PIPERACILLIN; RENAL REPLACEMENT THERAPIES; SIEVING COEFFICIENT; VIVO METHODS; VIVO STUDIES;

ANTIBIOTICS;

ALBUMIN; HEMOGLOBIN; MEROPENEM; PIPERACILLIN; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ARTICLE; CONTINUOUS HEMOFILTRATION; CONTROLLED STUDY; DRUG ADSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; FILTER CLEARANCE; HUMAN; RENAL SYSTEM PARAMETERS; SIEVING COEFFICIENT; BIOLOGICAL MODEL; HEMOFILTRATION; METABOLIC CLEARANCE RATE; STATISTICAL MODEL;

ANTI-BACTERIAL AGENTS; HEMOFILTRATION; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; THIENAMYCINS;

EID: 84942329031     PISSN: 03913988     EISSN: 17246040     Source Type: Journal    
DOI: 10.5301/ijao.5000422     Document Type: Article

References (41)

1. Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol. 2003;14(4):1022-1030.
2. Legrand M, Darmon M, Joannidis M, Payen D. Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med. 2013;39(1):101-108.
3. RENAL Study Investigators. Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey. Crit Care Resusc. 2008;10(3):225-230.
4. Ricci Z, Ronco C, D’Amico G, et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant. 2006;21(3):690-696.
5. Ronco C, Zanella M, Brendolan A, et al. Management of severe acute renal failure in critically ill patients: an international survey in 345 centres. Nephrol Dial Transplant. 2001;16(2):230-237.
6. Choi G, Gomersall CD, Tian Q, Joynt GM, Li AM, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif. 2010;30(3):195-212.
7. Seyler L, Cotton F, Taccone FS, et al. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011;15(3): R137.
8. Kronfol NO, Lau AH, Barakat MM. Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. ASAIO Trans. 1987;33(3):300-303.
9. Tian Q, Gomersall CD, Ip M, Tan PE, Joynt GM, Choi GY. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother. 2008;52(3): 1009-1013.
10. Lam PK, Tian Q, Ip M, Gomersall CD. In vitro adsorption of gentamicin and netilmicin by polyacrylonitrile and polyamide hemofiltration filters. Antimicrob Agents Chemother. 2010; 54(2):963-965.
11. Tian Q, Gomersall CD, Ip M, Joynt GM. Effect of preexposure to aminoglycosides on in vitro adsorption of amikacin by polyacrylonitrile hemofilters. Antimicrob Agents Chemother. 2011; 55(7):3641-3642.
12. Tian Q, Gomersall CD, Wong A, et al. Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. Int J Antimicrob Agents. 2006;28(2):147-150.
13. Choi G, Gomersall CD, Lipman J, et al. The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration an in vitro study of levofloxacin. Int J Antimicrob Agents. 2004;24(5):468-472.
14. Wagner CC, Steiner I, Zeitlinger M. Daptomycin elimination by CVVH in vitro: evaluation of factors influencing sieving and membrane adsorption. Int J Clin Pharmacol Ther. 2009;47(3):178-186.
15. Tian Q, Gomersall CD, Leung PP, et al. The adsorption of vancomycin by polyacrylonitrile, polyamide, and polysulfone hemofilters. Artif Organs. 2008;32(1):81-84.
16. Langgartner J, Vasold A, Glück T, Reng M, Kees F. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med. 2008;34(6):1091-1096.
17. Bilgrami I, Roberts JA, Wallis SC, et al. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2010;54(7):2974-2978.
18. Kielstein JT, Czock D, Schöpke T, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med. 2006;34(1):51-56.
19. Deshpande P, Chen J, Gofran A, Murea M, Golestaneh L. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED). Nephrol Dial Transplant. 2010;25(8):2632-2636.
20. Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2001;48(6):881-885.
21. Mueller SC, Majcher-Peszynska J, Hickstein H, et al. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother. 2002;46(5):1557-1560.
22. Arzuaga A, Maynar J, Gascón AR, et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol. 2005;45(2):168-176.
23. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JP. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(22):2039-2043.
24. US Food and Drug Administration. Guidance for industry: Bioanalytical method validation. FDA, 2001. [Accessed July 8, 2015] Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf
25. Jamal JA, Mat-Nor MB, Mohamad-Nor FS, et al. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents. 2015;45(1):41-45.
26. Jamal JA, Roberts DM, Udy AA, et al. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomized controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents. 2015;46(1):39-44.
27. Schroeder TH, Krueger WA, Hansen M, Hoffmann E, Dieterich HJ, Unertl K. Elimination of meropenem by continuous hemo(dia) filtration: an in vitro one-compartment model. Int J Artif Organs. 1999;22(5):307-312.
28. Arzuaga A, Isla A, Gascón AR, Maynar J, Corral E, Pedraz JL. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient. Blood Purif. 2006;24(4):347-354.
29. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract. 2003;94(4):94-98.
30. Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother. 1998;42(9): 2417-2420.
31. Meyer MM, Munar MY, Kohlhepp SJ, Bryant RE. Meropenem pharmacokinetics in a patient with multiorgan failure from Meningococcemia undergoing continuous venovenous hemodiafiltration. Am J Kidney Dis. 1999;33(4):790-795.
32. Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther. 1999;65(1):50-57.
33. Stevenson JM, Patel JH, Churchwell MD, et al. Ertapenem clearance during modeled continuous renal replacement therapy. Int J Artif Organs. 2008;31(12):1027-1034.
34. Lau AH, Pyle K, Kronfol NO, Libertin CR. Removal of cephalosporins by continuous arteriovenous ultrafiltration (CAVU) and hemofiltration (CAVH). Int J Artif Organs. 1989;12(6):379-383.
35. Phillips GJ, Davies JG, Olliff CJ, Kingswood C, Street M. Use of in vitro models of haemofiltration and haemodiafiltration to estimate dosage regimens for critically ill patients prescribed cefpirome. J Clin Pharm Ther. 1998;23(5):353-359.
36. Isla A, Gascón AR, Maynar J, Arzuaga A, Toral D, Pedraz JL. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin Ther. 2005;27(5): 599-608.
37. Isla A, Gascón AR, Maynar J, Arzuaga A, Sánchez-Izquierdo JA, Pedraz JL. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy. 2007; 53(3):194-201.
38. Gruber PC, Tian Q, Gomersall CD, Joynt GM, Choi GY. An in vitro study of the elimination of oseltamivir carboxylate by haemofiltration. Int J Antimicrob Agents. 2007;30(1): 95-97.
39. Vilay AM, Shah KH, Churchwell MD, Patel JH, DePestel DD, Mueller BA. Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapies. Blood Purif. 2010;30(1):37-43.
40. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif. 2006;24(5-6):548-554.
41. Isla A, Maynar J, Sánchez-Izquierdo JA, et al. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol. 2005;45(11):1294-1304.